Two pundits raised their price targets on the company.Before the market open on the last trading day of the week, two analysts tracking Genmab (GMAB 4.48%) stock felt compelled to raise their price targets on the biotech. This double-barreled blast of bullishness pushed the company's shares more than 4% higher that trading session, easily beating the essentially stagnant S&P 500 (^GSPC 0.01%). The petosemtamab effectNot surprisingly, both lifts were based largely on Genmab's latest acquisition. On Tuesday, ...